Sarepta Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 18.625 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.97B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ...